Fundraising Fox
Forus
Unicorn · $3B213 employees on LinkedIn · 9 known investors
Find your way into Forus
Sign up to see every warm intro you have to Forus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Forus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Forus embeds into physician workflows to automate the steps between a clinical decision and a patient starting treatment, including insurance authorization, financial assistance, and fulfillment routing across drugs, payers, and pharmacies. It also gives life sciences companies data on how medicines perform to inform research, drug launches, and investment decisions.
Also known as Tandem
Founders & leadership
Investors · 9
How we know: research · thesaasnews.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Atria Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · baincapitalventures.com · research · thesaasnews.com · Not right? Tell us
How we know: boxgroup.com · research · thesaasnews.com · Not right? Tell us
.png)
How we know: General Catalyst's portfolio page · research · thesaasnews.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pear VC's portfolio page · research · thesaasnews.com · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$150M disclosed across 1 of 4 rounds · 2026
- Undisclosed amountSeries CSep 2026Source ↗
- $150MSeries CSep 2026 · 6 sources
Bain Capital Ventures (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Company profile
researched Aug 2026Forus is a New York-based healthcare technology company, founded in 2023 by Sahir Jaggi and previously branded as Tandem, that operates an AI-powered network connecting physicians, pharmacies, payers and biopharma organizations. The platform is aimed at the coordination steps that sit between prescribing and dispensing: sources describe it automating insurance authorization, financial assistance and medication fulfillment workflows so that patients begin prescribed therapies faster and more reliably.
Commentary published after the company's May 2026 financing characterizes Forus as an operational routing or orchestration layer for specialty prescriptions rather than a conventional workflow SaaS product, positioning it at the transaction seams between healthcare stakeholders. The same analysis notes the company was expecting roughly $50 million in annualized revenue in 2026 and was valued at $1 billion in the round.
Reporting on the round is inconsistent in its labeling: one outlet describes a $123M Series B within a total of $160M raised since inception, while another describes the raise as a $160M Series C. Both cite an overlapping investor group led by Thrive Capital and General Catalyst.
Founding story
Sources state Forus was founded in 2023 by Sahir Jaggi, who was thirty-one at the time of the May 2026 financing, previously served as a partner at Rough Draft Ventures, and earned a biomedical research degree at Columbia. The company was previously branded as Tandem.
Business model
According to published analysis, Forus monetizes biopharma manufacturers downstream while providing the product free to providers and patients, a multi-sided model compared by the author to Visa and Google rather than to seat-license software.
Revenue is described as coming from biopharma manufacturers rather than from provider or patient seat licenses; the company was expected to reach approximately $50 million in annualized revenue in 2026.
Traction
Sources report approximately $50 million in expected annualized revenue for 2026 and a $1 billion valuation at the May 2026 financing.
Latest developments
In May 2026 Forus announced over $160M in equity financing at a $1 billion valuation, led by Thrive Capital and General Catalyst, with Accel, Bain Capital Ventures, Redpoint, BoxGroup and Pear VC participating. Proceeds are earmarked for expanding the AI network and scaling operations.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Described as an emerging orchestration or routing layer for specialty prescription access, valued at $1 billion at its May 2026 round on roughly $50 million of expected annualized revenue, a multiple noted as approximately 20x by one commentator. The company was reportedly little known among healthcare operators shortly before the round.
Positioned as infrastructure for transaction coordination between healthcare stakeholders rather than a point solution for prior authorization or a single-persona workflow application, with free distribution to providers and patients and monetization from biopharma.
Technology
An AI-powered platform that connects providers, pharmacies, payers and biopharma and automates insurance authorization, financial assistance and medication fulfillment workflows. Commentary frames AI as the mechanism that reduces the labor cost of bridging fragmentation between healthcare stakeholders, making orchestration commercially viable at scale.
Go-to-market
Physicians and provider organizations, pharmacies, payers, and biopharma manufacturers, with biopharma manufacturers identified as the paying customers; patients are the ultimate beneficiaries of faster therapy access.
Geography
Headquartered in New York; sources discuss the U.S. healthcare market.
History
Founded in 2023 and initially branded Tandem, the company had raised $160M in total equity funding by May 2026, including a $123M Series B reported by AlleyWatch and The SaaS News; a separate report characterized the $160M as a Series C. The financing, announced around May 12-18, 2026, valued the company at $1 billion.
Risks & controversies
Published analysis notes that incumbents in the specialty prescription stack — pharmacy benefit managers, hub services, specialty pharmacies and EHR vendors — are expected to contest the orchestration category. Reporting also conflicts on the round's label and size ($123M Series B versus $160M Series C), a discrepancy that is unresolved across the sources.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsThe SaaS News separately reported a $160M Series C at a $1 billion valuation backed by Thrive, General Catalyst and Accel, with capital to scale operations and enhance the AI platform.
$160M source ↗
The SaaS News reported a $123M Series B for the New York healthtech, bringing total equity funding to $160M, with Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup and Pear VC investing; proceeds to expand the AI-powered network.
$123M source ↗
Forus announced more than $160M in equity financing at a $1 billion valuation, led by Thrive Capital and General Catalyst with Accel, Bain Capital Ventures, Redpoint, BoxGroup and Pear VC; roughly $123M of the total was the Series B per AlleyWatch.
$160M source ↗
The company was previously branded as Tandem before operating as Forus; the source does not state the date of the change.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Forus triples valuation to $3B with new $150M funding roundfiercehealthcare.com · Sep 2026▸Research sources · 8
primary sources listed
- Forus Raises $123M Series Bthesaasnews.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Forus do?
- New York healthtech building an AI network linking doctors, pharmacies, payers and biopharma to speed patient access to therapies.
- Who founded Forus?
- Forus was founded by Sahir Jaggi.
- Who are Forus's investors?
- Forus's investors include Accel, Atria Ventures, avra, Bain Capital Ventures, BoxGroup, General Catalyst, Pear VC, Redpoint Ventures and 1 more.
- How much funding has Forus raised?
- Forus has disclosed $150M raised across 1 of its 4 known rounds.